Literature DB >> 25077788

Reply to Farmakiotis et al.

Claire S Waddington1, Thomas C Darton1, Brian Angus2, Andrew J Pollard1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25077788      PMCID: PMC4176429          DOI: 10.1093/cid/ciu561

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
To the Editor—Our recent development of a human Salmonella Typhi challenge model provided a detailed description of the clinical profile and associated pathological changes seen during typhoid fever [1]. Alterations in hematological parameters included decreases in hemoglobin and hematocrit in all participants, and, in those diagnosed with typhoid, decreases in both platelet and total white cell counts (WCCs). The reduction in WCC manifested as falls in neutrophil and eosinophil count, with the eosinophil count declining from 6 days prior to diagnosis. This was the earliest of all the blood parameters to change and was seen in all but 1 participant. Eosinopenia in our study was part of a general suppression of hematopoiesis, possibly consequent to infiltration of the bone marrow by Salmonella Typhi. As Farmakiotis et al note, the finding of eosinopenia has previously been reported in typhoid, although not universally. For example, in 2 series of 28 and 54 children with typhoid, eosinopenia occurred in 71.4% and 86.6%, respectively [2, 3]. Similarly, 10 of 17 returning travelers with typhoid fever were eosinopenic [2]. These data call into question the diagnostic value of the eosinophil count in isolation, and highlight the need to assess the clinical picture in its entirety. Clinical diagnosis of typhoid fever is challenging, particularly in endemic settings where the presentation can be indistinguishable from other common febrile diseases including malaria and dengue fever [4]. The data presented by Farmakiotis et al in their correspondence pertain to nontyphoidal Salmonella gastroenteritis, which is pathologically distinct from typhoid fever. Typhoid fever is a severe systemic infection caused by the human-restricted pathogen S. Typhi, affecting an estimated 26.9 million people annually, of whom 1% die [5]. In contrast, Salmonella gastroenteritis results from a large number of nonhuman restricted Salmonella serovars and is self-limiting in nonimmunosuppressed hosts. Eosinopenia is recognized in a variety of infectious diseases and in sepsis syndrome [6, 7]; however the underlying mechanism in infection, and more specifically in typhoid infection, is unclear. In health, eosinophils principally reside at mucosal surfaces including the gut mucosa [8], and it is possible that increased marginalization of these cells during infection at this site may account for the early and marked decrease [9]. These uncertainties highlight the significant gaps remaining in our understanding of both typhoid and other enteric infections as well as more global mechanisms of the mucosal immune response. Both need to be addressed to meaningfully impact the clinical management of patients and vaccination strategies. Human challenge studies provide an ideal setting to enable the detailed investigation of disease and immunobiology, particularly for human-restricted pathogens such as Salmonella Typhi [10]. Both our report and those of Farmakiotis and colleagues further highlight the lack of accurate diagnostic tests for typhoid and other Salmonella serovars, especially in endemic regions where resources are frequently limited. Prompt diagnosis and treatment of typhoid decreases complications and limits the opportunity for onward transmission [4]. New, reliable diagnostic tests are needed to prevent treatment delays, minimize morbidity and mortality, prevent inappropriate use of antimicrobials, and provide reliable epidemiological data.
  10 in total

Review 1.  Typhoid fever.

Authors:  Christopher M Parry; Tran Tinh Hien; Gordon Dougan; Nicholas J White; Jeremy J Farrar
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

2.  An analysis of children with typhoid fever admitted in 1991.

Authors:  C T Deshmukh; U B Nadkarni; S C Karande
Journal:  J Postgrad Med       Date:  1994 Oct-Dec       Impact factor: 1.476

Review 3.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

4.  Eosinopenia: Is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital?

Authors:  Hamid Shaaban; Sunil Daniel; Raymond Sison; Jihad Slim; George Perez
Journal:  J Crit Care       Date:  2010-12       Impact factor: 3.425

Review 5.  The eosinophil.

Authors:  P B Beeson; D A Bass
Journal:  Major Probl Intern Med       Date:  1977

6.  Typhoid Fever in an inner city hospital: a 5-year retrospective review.

Authors:  Dimitrios Farmakiotis; Julie Varughese; Paul Sue; Phyllis Andrews; Mary Brimmage; Joanna Dobroszycki; Christina M Coyle
Journal:  J Travel Med       Date:  2012-11-27       Impact factor: 8.490

Review 7.  Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies.

Authors:  Claire S Waddington; Thomas C Darton; William E Woodward; Brian Angus; Myron M Levine; Andrew J Pollard
Journal:  J Infect       Date:  2014-01-31       Impact factor: 6.072

8.  Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units.

Authors:  Khalid Abidi; Ibtissam Khoudri; Jihane Belayachi; Naoufel Madani; Aicha Zekraoui; Amine Ali Zeggwagh; Redouane Abouqal
Journal:  Crit Care       Date:  2008-04-24       Impact factor: 9.097

9.  Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010.

Authors:  Geoffrey C Buckle; Christa L Fischer Walker; Robert E Black
Journal:  J Glob Health       Date:  2012-06       Impact factor: 4.413

10.  An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution.

Authors:  Claire S Waddington; Thomas C Darton; Claire Jones; Kathryn Haworth; Anna Peters; Tessa John; Ben A V Thompson; Simon A Kerridge; Robert A Kingsley; Liqing Zhou; Kathryn E Holt; Ly-Mee Yu; Stephen Lockhart; Jeremy J Farrar; Marcelo B Sztein; Gordon Dougan; Brian Angus; Myron M Levine; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2014-02-10       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.